PubRank

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Clinical Trial ID NCT00678392

PubWeight™ 44.27‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00678392

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011 12.13
2 Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 2013 3.79
3 Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. Eur Urol 2014 2.23
4 Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 2013 1.65
5 Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015 1.53
6 Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs. Oncologist 2011 1.30
7 Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 2011 1.26
8 Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012 1.20
9 Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 2012 1.19
10 AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 2012 1.17
11 Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 2011 1.16
12 Development of second-generation VEGFR tyrosine kinase inhibitors: current status. Curr Oncol Rep 2011 1.14
13 Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol 2013 1.10
14 Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol 2011 1.08
15 Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial. Br J Cancer 2014 1.06
16 Tumor stroma as targets for cancer therapy. Pharmacol Ther 2012 1.06
17 Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011 1.01
18 Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol 2014 0.96
19 NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 2011 0.94
20 Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer 2014 0.93
21 A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting. PLoS One 2015 0.88
22 Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 2015 0.84
23 Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol 2010 0.81
24 Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies. Oncologist 2010 0.81
25 Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. Int J Nephrol Renovasc Dis 2014 0.77
26 Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol 2016 0.76
27 Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma. Eur Urol 2016 0.75
28 Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Biologics 2010 0.75
29 Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors. Clin Med Insights Oncol 2010 0.75
30 Targeted therapies for renal cell carcinoma: more gains from using them again. Curr Oncol 2009 0.75
31 State-of-the-art treatment of metastatic renal cell carcinoma. Curr Oncol 2009 0.75
Next 100